Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

2065 PWToday Stories

Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma

01 May 17

Genmab A/S announced today that the European Commission (EC) has granted a marketing authorization for DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.  The EC approval follows a positive opinion issued for DARZALEX by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in February 2017. This approval also converts the previous conditional marketing authorization for DARZALEX to a full approval.  DARZALEX is being developed under an August 2012 agreement in which Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize the product.

Genmab will receive milestone payments totaling USD 48 million from Janssen Biotech, Inc. in connection with the first commercial sales of DARZALEX under the expanded label. The sales are expected to occur quickly after the approval.  These milestone payments were included in the financial guidance issued by Genmab on February 22, 2017 and therefore there is no change to the company’s financial guidance following this approval.  

“We are very pleased that DARZALEX is now approved in Europe in combination with other standard multiple myeloma therapies and that a far greater number of patients suffering from this incurable disease will now have access to this first-in-class immunotherapy,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.